Last reviewed · How we verify
Cyclophosphamide and ATG
Cyclophosphamide and ATG work together to suppress the immune system by eliminating lymphocytes, allowing immune reconstitution and halting autoimmune disease progression.
Cyclophosphamide and ATG work together to suppress the immune system by eliminating lymphocytes, allowing immune reconstitution and halting autoimmune disease progression. Used for Severe aplastic anemia, Systemic sclerosis with organ involvement.
At a glance
| Generic name | Cyclophosphamide and ATG |
|---|---|
| Also known as | Sendoxan |
| Sponsor | Haukeland University Hospital |
| Drug class | Immunosuppressive combination therapy |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is an alkylating agent that causes DNA cross-linking and induces lymphocyte apoptosis, while ATG (anti-thymocyte globulin) is a polyclonal antibody that directly targets and depletes T cells. Together, this combination achieves profound immunosuppression followed by immune reset, used primarily in severe autoimmune conditions like aplastic anemia and systemic sclerosis.
Approved indications
- Severe aplastic anemia
- Systemic sclerosis with organ involvement
Common side effects
- Infection (bacterial, viral, fungal)
- Hemorrhage
- Nausea and vomiting
- Alopecia
- Infertility
- Secondary malignancy
- Serum sickness
Key clinical trials
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation (PHASE3)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamide and ATG CI brief — competitive landscape report
- Cyclophosphamide and ATG updates RSS · CI watch RSS
- Haukeland University Hospital portfolio CI